DescriptionCurator's Comment:: The description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00046 | https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21017lbl.pdf
Curator's Comment:: The description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00046 | https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21017lbl.pdf
Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Chemically, insulin lispro is Lys(B28), Pro(B29) human insulin analog, created when the amino acids at positions 28 and 29 on the insulin B-chain are reversed. Insulin lispro is synthesized in a special non-pathogenic laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for insulin lispro. Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin lispro products. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis. Insulin lispro begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Humalog is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.
CNS Activity
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | HUMALOG MIX Approved UseHumalog Mix75/25, a mixture of 75% insulin lispro protamine suspension and 25% insulin lispro injection, (rDNA origin), is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia. Humalog Mix75/25 has a more rapid onset of glucose-lowering activity compared with Humulin 70/30 while having a similar duration of action. This profile is achieved by combining the rapid onset of Humalog with the intermediate action of insulin lispro protamine suspension. Launch Date9.4573442E11 |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175453
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
||
|
NCI_THESAURUS |
C581
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
||
|
NDF-RT |
N0000004931
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
||
|
WHO-ATC |
A10AB04
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
||
|
WHO-VATC |
QA10AC04
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
||
|
WHO-VATC |
QA10AD04
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
||
|
NDF-RT |
N0000004931
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
||
|
WHO-VATC |
QA10AB04
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
||
|
WHO-ATC |
A10AD04
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
||
|
WHO-ATC |
A10AC04
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
||
|
NDF-RT |
N0000004931
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
GFX7QIS1II
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | |||
|
SUB128662
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | |||
|
CHEMBL1201611
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | |||
|
86009
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | RxNorm | ||
|
M6300
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | Merck Index | ||
|
C29123
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | |||
|
118984450
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | |||
|
SUB08198MIG
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | |||
|
133107-64-9
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | |||
|
5002
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | |||
|
D061268
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | |||
|
DB00046
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | |||
|
133107-64-9
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | |||
|
SUB128661
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | |||
|
1342321
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | USP-RS | ||
|
INSULIN LISPRO
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | |||
|
7278
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY | |||
|
CHEMBL1201538
Created by
admin on Fri Jun 25 20:51:56 UTC 2021 , Edited by admin on Fri Jun 25 20:51:56 UTC 2021
|
PRIMARY |
ACTIVE MOIETY